These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 23909036)

  • 1. [Current possibilities of targeted therapy in the treatment of breast cancer with overexpression of HER-2/neu and metastatic lesions in the brain].
    Naskhletashvili DR; Gorbunova VA; Moskvina EA
    Vopr Onkol; 2013; 59(3):347-51. PubMed ID: 23909036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcomes in patients who received lapatinib plus capecitabine combination therapy for HER2-positive breast cancer with brain metastasis and a comparison of survival with those who received trastuzumab-based therapy: a study by the Anatolian Society of Medical Oncology.
    Kaplan MA; Isikdogan A; Koca D; Kucukoner M; Gumusay O; Yildiz R; Dayan A; Demir L; Geredeli C; Kocer M; Arslan UY; Inal A; Akman T; Coskun U; Sener N; Inanc M; Elkiran ET; Ozdemir NY; Durnalı AG; Suner A; Alici S; Tarhan MO; Boruban C; Oksuzoglu B; Urakci Z
    Breast Cancer; 2014 Nov; 21(6):677-83. PubMed ID: 23335064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longest progression-free survival with lapatinib and capecitabine combination followed by trastuzumab in HER2-positive brain metastatic breast cancer.
    Şendur MA; Uncu D; Zengin N
    Med Oncol; 2014 Apr; 31(4):890. PubMed ID: 24535609
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine.
    Metro G; Foglietta J; Russillo M; Stocchi L; Vidiri A; Giannarelli D; Crinò L; Papaldo P; Mottolese M; Cognetti F; Fabi A; Gori S
    Ann Oncol; 2011 Mar; 22(3):625-630. PubMed ID: 20724575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metastatic breast cancer treated with lapatinib with a prolonged benefit: a case report and a review of therapeutic options available.
    Bianchi GV; Duca M; Sica L; Mariani G
    Tumori; 2013; 99(6):269e-72e. PubMed ID: 24503801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complete response of brain metastases from breast cancer overexpressing Her-2/neu to radiation and concurrent Lapatinib and Capecitabine.
    Abboud M; Saghir NS; Salame J; Geara FB
    Breast J; 2010; 16(6):644-6. PubMed ID: 21070441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lapatinib plus capecitabine resolved human epidermal growth factor receptor 2-positive brain metastases.
    Glück S; Castrellon A
    Am J Ther; 2009; 16(6):585-90. PubMed ID: 19287304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term disease control with lapatinib and capecitabine in a patient with HER2-positive metastatic breast cancer pretreated with trastuzumab and trastuzumab-emtansine.
    De Angelis C; Milano M; Gargiulo P; Stanzione B; Forestieri V; Lauria R; Pensabene M; D'Arco F; De Placido S; Arpino G
    Tumori; 2013; 99(3):e131-3. PubMed ID: 24158083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer.
    Welslau M; Diéras V; Sohn JH; Hurvitz SA; Lalla D; Fang L; Althaus B; Guardino E; Miles D
    Cancer; 2014 Mar; 120(5):642-51. PubMed ID: 24222194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid tumor shrinkage with lapatinib plus capecitabine in a patient with massive liver involvement.
    Giotta F; Latorre A; Cramarossa A; Simone G; Florio C; Oliva S; Lorusso V
    Tumori; 2013; 99(6):278e-81e. PubMed ID: 24503803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.
    Krop IE; LoRusso P; Miller KD; Modi S; Yardley D; Rodriguez G; Guardino E; Lu M; Zheng M; Girish S; Amler L; Winer EP; Rugo HS
    J Clin Oncol; 2012 Sep; 30(26):3234-41. PubMed ID: 22649126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lapatinib plus capecitabine for HER2-positive advanced breast cancer: a multicentre study of Anatolian Society of Medical Oncology (ASMO).
    Cetin B; Benekli M; Turker I; Koral L; Ulas A; Dane F; Oksuzoglu B; Kaplan MA; Koca D; Boruban C; Yilmaz B; Sevinc A; Berk V; Uncu D; Harputluoglu H; Coskun U; Buyukberber S
    J Chemother; 2014 Oct; 26(5):300-5. PubMed ID: 24112786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unusual long-lasting cutaneous complete response to lapatinib and capecitabine in a heavily pretreated HER2-positive plurimetastatic breast cancer patient.
    Pizzuti L; Sergi D; Barba M; Vici P
    Tumori; 2013; 99(3):e127-30. PubMed ID: 24158082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A systematic review of dual targeting in HER2-positive breast cancer.
    Kümler I; Tuxen MK; Nielsen DL
    Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast cancer brain metastases responding to lapatinib plus capecitabine as second-line primary systemic therapy.
    Bergen ES; Berghoff AS; Rudas M; Preusser M; Bartsch R
    Anticancer Drugs; 2015 Jun; 26(5):579-81. PubMed ID: 25714248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
    Pivot X; Manikhas A; Żurawski B; Chmielowska E; Karaszewska B; Allerton R; Chan S; Fabi A; Bidoli P; Gori S; Ciruelos E; Dank M; Hornyak L; Margolin S; Nusch A; Parikh R; Nagi F; DeSilvio M; Santillana S; Swaby RF; Semiglazov V
    J Clin Oncol; 2015 May; 33(14):1564-73. PubMed ID: 25605838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer.
    Saura C; Garcia-Saenz JA; Xu B; Harb W; Moroose R; Pluard T; Cortés J; Kiger C; Germa C; Wang K; Martin M; Baselga J; Kim SB
    J Clin Oncol; 2014 Nov; 32(32):3626-33. PubMed ID: 25287822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea.
    Ro J; Park S; Kim S; Kim TY; Im YH; Rha SY; Chung JS; Moon H; Santillana S
    BMC Cancer; 2012 Jul; 12():322. PubMed ID: 22839200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Systemic treatment of brain metastases from breast cancer: cytotoxic chemotherapy and targeted therapies].
    Bachelot T; Le Rhun E; Labidi-Gally I; Heudel P; Gilabert M; Bonneterre J; Pierga JY; Gonçalves A
    Bull Cancer; 2013 Jan; 100(1):7-14. PubMed ID: 23305997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Over 17-month complete clinical brain response with a well-tolerated lapatinib plus capecitabine combination in a very young patient afflicted by HER2-positive metastatic breast cancer.
    Sini V; Menghi A; Cursano MC; Mandolini PL; Lanza R
    Tumori; 2013; 99(6):273e-7e. PubMed ID: 24503802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.